OS Therapies is a clinical-stage cancer immunotherapy company developing HER2-targeted therapies to activate the immune system against osteosarcoma and other solid tumors. The company addresses the lack of effective treatments for osteosarcoma, which has seen over 30 years without new options, by leveraging its proprietary OST-tADC platform to enhance therapeutic efficacy.
Funding
$7.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Osteosarcoma, a type of bone cancer, has seen limited therapeutic advancements in over three decades, leaving a significant unmet need for effective treatments, especially for patients with HER2-expressing tumors. Current treatment options often fail to provide long-term remission, highlighting the urgent requirement for innovative therapies for both pediatric and adult patients.
Solution
OS Therapies is developing HER2-targeted immunotherapies designed to activate the patient's immune system to fight osteosarcoma and other solid tumors. Their approach leverages the OST-tADC platform, a tunable Antibody Drug Conjugate silicone linker technology, to enhance therapeutic efficacy. By targeting the HER2 gene, which is implicated in a substantial portion of osteosarcoma cases, the immunotherapy aims to stimulate killer T cells against all cancer antigens expressed by the tumor. This strategy has the potential to offer a more effective and durable response compared to existing treatments. The company's lead candidate is initially focused on addressing the urgent need for new osteosarcoma therapies, with plans to expand into other HER2-expressing cancers such as breast, esophageal, lung, ovarian, and pancreatic cancers.
Target Audience
The primary target audience includes patients diagnosed with osteosarcoma and other HER2-expressing solid tumors, as well as oncologists and medical professionals seeking innovative treatment options for these cancers.
Features
- HER2-targeted immunotherapy designed to activate killer T cells against cancer antigens.
- OST-tADC platform for tunable Antibody Drug Conjugate delivery.
- Focus on HER2-expressing osteosarcoma and other solid tumors.
- Potential for expansion into breast, esophageal, lung, ovarian, and pancreatic cancers.